Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The release does not mention cost or whether it’s covered by private insurance or Medicare, and in this case, it’s a pretty big omission. This may be an enormously expensive treatment for patients — and it’s why we have a cost criterion in our reviews. The hopeful psoriasis patient who sees this release without a cost discussion might already have their hand on the phone to call their dermatologist. Here’s a very rough estimate of what that patient might face in terms of cost: Based on a conservative wholesale price of roughly $4,000 per 80 mg injection and following the recommendation (found on the package insert) of two injections every two weeks for 12 weeks, followed by monthly injections, we calculated $48,000 for the first 12 weeks plus $36,000 for the following 9 months or $84,000 total. The release stated that by week 12, “76.4 to 81.8 percent of patients had their psoriasis classified as “clear” or “minimal” compared to 3.2% of patients on the placebo. By the 60th week, 68.7 to 78.3 percent of patients had maintained their improvement.” We also wanted more detail on the measured strength of the response for each patient. For example, what constitutes “minimal”? The release adequately addresses harms and notes that long-term side effects are unknown with this sentence: “Adverse events associated with ixekizumab included slightly higher rates of neutropenia (low white blood cell count), yeast infection and inflammatory bowel disease compared to the placebo. The safety of therapy longer than 60 weeks will need to be monitored in the future.” The release clearly and thoroughly describes the three phase 3 international trials at 21 sites, that they enrolled a large number of patients, and that they were randomized and controlled. There was no disease mongering. The release describes what psoriasis is and its prevalence, and explains that these trials were for moderate to severe psoriasis which covers at least 10 percent of the body. The release is very transparent in stating that the drug manufacturer paid for the research and that the lead researcher is a paid consultant to Eli Lilly. The release did not compare the many different ways that patients treat psoriasis, some with topical agents and some with oral steroids or other medications. The release states that the drug has been approved by the FDA following the completion of the trials. This is a strong indication that the drug is or soon will be available. The release should have noted that the drug is already being marketed under the brand name Taltz. The release makes an understated claim to novelty with this quote from the lead researcher: “Ten years ago, we thought complete clearance of this disease was impossible. It wasn’t something we would even try to do. Now with this drug, we’re obtaining response levels higher than ever seen before.” There was no unjustifiable language in the release.

Output: New drug clears psoriasis in clinical trials


Input: Consider Input: The Utah Senate and House of Representatives voted unanimously Monday evening during a special session to send the proposal to Republican Gov. Gary Herbert’s desk. The measure would replace plans for an unusual state-run dispensary system with 14 privately run pharmacies and adopt protections for patients who are concerned they could be prosecuted for drug crimes, among other changes. Utah backtracked from the state-run dispensary after county attorneys expressed concern that such a system would put public employees at risk of being prosecuted under federal drug laws. Republican Senate Majority Leader Evan Vickers, who drafted the law, said his team is “doing everything we can” to improve patient access and have product ready by next March. Some lawmakers said they still have heartburn over certain aspects of the bill, sharing reservations about product distribution and a looming fear of federal prosecution. Democratic Sen. Derek Kitchen said he’s concerned patients in rural parts of the state may have to pay more to access marijuana. Before the House vote, Republican Rep. Keven Stratton suggested Utah seek a federal waiver to protect the state program from prosecution under federal drug laws. Marijuana is banned at the federal level, though a congressional amendment blocks the Justice Department from interfering with states’ medical marijuana programs. The measure dictated that the courts may not treat a medical marijuana patient differently than someone who uses any other prescribed, controlled substance. Another change prohibited the state from issuing cultivation and pharmacy licenses to legislators. “A lot of money flows through this industry, some back to legislators,” Vickers said. “We don’t want legislators to have undue influence in an industry they want to have ownership in.” Debates in the chamber reflected ongoing tensions over amendments regarding distribution and prosecution of drug crimes. During a tense public hearing last week, members of the conservative group Utah Eagle Forum lamented the loss of the state-run dispensary system, while some medical marijuana advocates raised concern that there wouldn’t be enough private dispensaries to meet growing patient demand. An earlier version of the law imagined 12 privately run dispensaries instead of the state-run system. In the same meeting, a proposal outlining patient protections caused an emotional back-and-forth between conservative attorneys who argued parents couldn’t take care of children while using marijuana and patients who said the drug makes them better caretakers and helps them manage their pain. Utah residents voted to legalize medical marijuana via ballot measure in November. The revised law became effective in December after a compromise that secured the support of The Church of Jesus Christ of Latter-day Saints and some marijuana advocates. However, the deal drew backlash from other advocates as it banned many marijuana edibles, placed additional restrictions on growing cannabis and made fewer medical conditions eligible for treatment with pot. Other changes addressed issues with land ordinances for cultivation facilities and marijuana research at in-state universities. Marijuana advocates said they are optimistic about the changes adopted. “There’s a light at the end of the tunnel, we see legislators working together, and they’re willing to work out a plan for patients,” Desiree Hennessy, director of the Utah Patients Coalition, said. Republican Rep. Brad Daw acknowledged the measure as a good first step but expects additional changes to the program in January. “I have close friends who, for them, cannabis is the only option, it relieves the kind of pain they have ... we have every right and responsibility to work toward a law that allows medical cannabis to patients who need it,” he said. “Is this bill perfect? Of course not. Is this done? No, it’s not.”

Output: Utah lawmakers approve changes to medical cannabis law.


Input: Consider Input: Clark County Public Health says people who visited PeaceHealth Urgent Care - Memorial in Vancouver in the afternoon Dec. 31 may have been exposed. The Oregon Health Authority said a measles case was confirmed in a person who spent time in The Dalles and Hood River. People in The Dalles may have been exposed Dec. 29 at the Discovery Center or Dec. 31 at Fred Meyer. People in Hood River may have been exposed Dec. 30 if they were at Doppio Cafe, Goodwill or Full Sail Brewery in the early afternoon. People who were at the Oregon Health & Science University Emergency Department Jan. 2 in the morning may have been exposed. Officials advise anyone who may have measles symptoms to call before visiting a medical office. Measles symptoms begin with a fever, cough, runny nose and red eyes, followed by a rash.


Output: Measles cases confirmed in Vancouver and Portland.